



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 7/16</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/16736</b> <b>(43) International Publication Date:</b> 30 March 2000 (30.03.00)
<b>(21) International Application Number:</b> PCT/EP99/07380 <b>(22) International Filing Date:</b> 20 September 1999 (20.09.99) <b>(30) Priority Data:</b> 98307733.0 23 September 1998 (23.09.98) EP <b>(71) Applicant (for all designated States except AU BB CA CR CY DM GB GD GH IE IL KE LK LS MN MW NZ SD SG SZ TT TZ UG ZA):</b> UNILEVER N.V. [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL). <b>(71) Applicant (for AU BB CA CR CY DM GB GD GH IE IL KE LK LS MN MW NZ SD SG SZ TT TZ UG ZA only):</b> UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London, Greater London EC4P 4BQ (GB). <b>(72) Inventors:</b> CREETH, Jonathan; Unilever Research Colworth, Colworth House, Sharnbrook, Bedfordshire MK44 1LQ (GB). MOLLOY, Keiran; University of Bath, Bath, Devon BA2 7AY (GB). WRIGHT, Philip; University of Bath, Bath, Devon BA2 7AY (GB). <b>(74) Agent:</b> KAN, Jacob; Unilever Research Vlaardingen, Olivier van Noortlaan 120, NL-3133 AT Vlaardingen (NL).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ORAL CARE COMPOSITIONS  <b>(57) Abstract</b>  The invention relates to an oral care composition with antiplaque agents. The antiplaque agents are complexes of divalent copper, zinc, iron or tin, or trivalent iron with a specific class of cyclic $\alpha$ -hydroxyketones. A typical example is the copper(II)-ethylmaltol complex. These complexes are more active antiplaque agents than e.g. copper-hinokitiol complexes.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

### "Oral Care Compositions"

The present invention relates to oral care compositions comprising particular antiplaque agents. More particularly, it relates to oral care compositions comprising certain copper, zinc, iron or tin metal complexes comprising biologically active ligands as antiplaque agents.

It is already known, that copper and zinc metals complexes comprising certain biologically active ligands have an antimicrobial activity. Thus, for example, in EP-A-0728478 (Otsuka Pharmaceutical Co., Ltd.), copper-hinokitiol and zinc-hinokitiol complexes are described, which are stated to have antimicrobial activity. According to this publication, these copper- and zinc-hinokitiol complexes can be usefully included in oral care compositions.

Hinokitiol is 4-isopropyl tropolone, a cyclic  $\alpha$ -hydroxyketone having the structure



We have now found that a different class of cyclic  $\alpha$ -


hydroxyketones are biologically active ligands, capable of forming complexes with copper, zinc, iron and tin, said complexes

having an antiplaque activity which is superior to the  
5 aforementioned copper- and zinc-hinokitiol complexes.

The class of cyclic  $\alpha$ -hydroxyketones according to the present invention is represented by the following general structural formula:

10

15



20 in which X represents O or NR<sub>3</sub>, R<sub>1</sub> and R<sub>3</sub> represent H or a C<sub>1</sub>-C<sub>16</sub>, preferably a C<sub>1</sub>-C<sub>4</sub> branched or straight-chain alkylgroup, and R<sub>2</sub> represents H or a hydroxymethylgroup. The link between the carbon atoms in the ring structure at positions 2 and 3 can be saturated or unsaturated, and is  
25 preferably unsaturated.

This class of cyclic  $\alpha$ -hydroxyketones embraces, therefore, derivatives of hydroxypyran-4-ones and hydroxypyridin-4-ones. Typical examples of these cyclic  $\alpha$ -hydroxyketones are  
30 maltol (= 3-hydroxy-2-methyl-4H-pyran-4-one), X being O, R<sub>1</sub> being methyl and R<sub>2</sub> being H; ethylmaltol (3-hydroxy-2-ethyl-4H-pyran-4-one), X being O, R<sub>1</sub> being ethyl and R<sub>2</sub> being H; kojic acid (5-hydroxy-2-(hydroxymethyl)-4H-pyran-

4-one), X being O, R<sub>1</sub> being H and R<sub>2</sub> being hydroxymethyl;  
2-methyl-3-hydroxypyridin-4-one, X = NR<sub>3</sub>, R<sub>3</sub> = H, R<sub>1</sub> =  
methyl and R<sub>2</sub> = H; 1,2-dimethyl-3-hydroxypyridin-4-one, X =  
NR<sub>3</sub>, R<sub>3</sub> = methyl, R<sub>1</sub> = methyl and R<sub>2</sub> = H; and 1-ethyl-2-  
5 methyl-3-hydroxypyridin-4-one, X = NR<sub>3</sub>, R<sub>3</sub> = ethyl, R<sub>1</sub> =  
methyl and R<sub>2</sub> = H.

The metals which are complexed by the above class of cyclic  
α-hydroxyketones are divalent copper, zinc, iron and tin  
10 and trivalent iron.

The cyclic α-hydroxyketones of the present invention, and  
the metal complexes thereof, are known in the art and can  
be synthesised by established methodologies, as e.g.  
15 described in Acta Cryst. B32 (1976) page 3121 by Berg, et  
al., in Can. J. Chem. 68, (1990) page 1598 by Annan, et  
al., J. Chem. Soc., Dalton Trans. (1992) page 2375 by  
Denekamp, et al., in J. Med. Chem. 37 (1994) page 461 by El-  
Jammal, et al., and in J. Med. Chem. 39 (1996) page 3659 by  
20 Ellis, et al.. Suitable complexes can be formed from a  
suitable divalent copper, zinc, iron or stannous salt or a  
trivalent iron salt with the cyclic α-hydroxyketones in  
molar ratios of between 10:1 to 1:10, preferably 4:1 to  
1:4, particularly preferably 2:1 to 1:2 (the molar ratio  
25 being calculated on the basis of the metal ion).

The preferred metal complexes according to the present  
invention are the Cu<sup>2+</sup> and Sn<sup>2+</sup> complexes, particularly the  
Cu<sup>2+</sup>- and Sn<sup>2+</sup>- maltol and -ethylmaltol complexes.

30

The metal complexes of the present invention are included  
in the oral care compositions in an amount, ranging from  
0.001 to 5 % by weight of the composition, preferably 0.1

to 3 % by weight, and optimum results are obtained with amounts, ranging from 0.2 to 2 by weight of the composition. Mixtures of the various metal complexes may also be used. The complexes may be prepared prior to their  
5 incorporation in the oral care composition, or they may be prepared in situ during the manufacture of the oral care composition. It may sometimes be advantageous to use an amount of the cyclic  $\alpha$ -hydroxyketone, in excess of the stoichiometric equivalent, required for the formation of the  
10 complex, to prevent possible decomposition of the complexes in the oral care composition during storage, and to possibly further increase the antiplaque activity of the complexes. It has also been found that it is sometimes advantageous to use an excess of the metal salt, e.g. the  
15 copper or stannous salt; to further increase the antiplaque activity.

The oral care compositions of the present invention may furthermore comprise optional, conventional ingredients  
20 such as pharmaceutically acceptable carriers like starch, sucrose, water or water/alcohol systems etc.. Small amounts of surfactants may also be included, such as anionic, nonionic, cationic and zwitterionic or amphoteric surfactants. They may comprise particulate abrasive  
25 materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, calcium pyrophosphates, hydroxyapatites, trimetaphosphates, insoluble hexametaphosphates and so on, including agglomerated particulate abrasive materials, usually in amounts between  
30 3 and 60% by weight. In the case of calcium carbonates being used as the abrasive materials, the metal complexes of the present invention are more compatible with such materials than other metal salts, e.g. copper salts, which

are according to EP-B-38867 (Blendax) rather incompatible with calcium carbonates.

Furthermore, they may comprise humectants such as glycerol, sorbitol, propyleneglycol, xylitol, lactitol and so on.

Binders and thickeners such as sodium carboxymethyl-cellulose, xanthan gum, gum arabic etc. may also be included, as well as synthetic polymers such as polyacrylates and carboxyvinyl polymers such as Carbopol®.

Flavours such as peppermint and spearmint oils may also be included, as well as preservatives, opacifying agents, colouring agents, pH-adjusting agents, sweetening agents and so on.

Additional anti-bacterial agents may also be included such as Triclosan, chlorhexidine, copper-, zinc- and stannous salts such as zinc citrate, sodium zinc citrate and stannous pyrophosphate, sanguinarine extract, metronidazole. Further examples of anti-bacterial agents are quaternary ammonium compounds such as cetylpyridinium chloride; bis-guanides such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; halogenated bisphenolic compounds such as 2,2' methylenebis-(4-chloro-6-bromophenol).

Polymeric compounds which can enhance the delivery of active ingredients such as anti-bacterial agents can also be included. Examples of such polymers are copolymers of polyvinylmethylether with maleic anhydride and other similar delivery enhancing polymers, e.g. those described in DE-A-3,942,643 (Colgate)

While the complexes of the present invention are particularly useful as anti-plaque agents, they are also useful as antimicrobial- and anti-gingivitis agents in oral  
5 care products.

Furthermore anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc. may also be included.

10

Anti-carries agents such as sodium- and stannous fluoride, aminefluorides, sodium monofluorophosphate, casein, plaque buffers such as urea, calcium lactate, calcium glycerophosphate, strontium polyacrylates may also be  
15 included. Other optional ingredients include vitamins such as Vitamin C, and plant extracts. Desensitizing agents such as glycerolmonooleate potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate as well as strontium  
20 salts may also be included.

Buffers and salts to buffer the pH and ionic strength of the compositions may also be included. Liposomes and other encapsulates may also be used to improve delivery or  
25 stability of active ingredients.

Furthermore, the oral compositions may comprise anti-calculus agents such as alkalimetal pyrophosphates, hypophosphite-containing polymers, organic phosphonates,  
30 phosphocitrates etc..

In addition, the compositions may comprise functional biomolecules such as bacteriocins, antibodies, enzymes and



so on.

Other optional ingredients that may be included are e.g. bleaching agents such as peroxy compounds e.g. potassium  
5 peroxydiphosphate, effervescing systems such as sodium bicarbonate/citric acid systems, colour change systems, and so on.

The toothpastes may also be formulated into systems for use  
10 in dual-compartment type dispensers.

The present invention will be further illustrated by way of Example.

**Example 1**

In vitro biofilm antiplaque tests were carried out with copper salts, and copper complexes of hinokitiol and maltol.

The test is based on monitoring the growth (by measuring absorbance) of a biofilm of a single species of bacteria, formed in the wells of a 96 well plate, after treatment with toothpaste slurries, and calculating the time taken to reach a chosen turbidity (i.e. a chosen absorbance value at 630nm)

A sample of *S. warneri* was cultured overnight in BHI medium. The culture was centrifuged and washed twice with phosphate-buffered saline (PBS) to an approximate optical density of 1.0. A 200 µl aliquot of bacterial suspension was pipetted into wells of a maleic anhydride-activated polystyrene 96-well plate (Pierce-Warriner, Chester). Plates were covered with a sterile plate sealer (to prevent contamination), centrifuged (3000 rpm, 4 minutes) and incubated for 1 hour at 37°C. Plates were used on the day of preparation, and were kept until use at room temperature, or if not required for several hours, at 4°C. Biofilm-coated wells were washed three times with PBS taking care to avoid disrupting the bacteria.

Toothpaste slurries were prepared by mixing paste with water to give 33% (w/w) slurries and centrifuging for 10 or 20 minutes at 3,500 rpm (Heraeus Labofuge 400 or MSE Mistral 1000 centrifuge). The supernatant was decanted into sterile containers and used within a day.

After washing plates, wells were treated with 200  $\mu$ l of toothpaste supernatant for 30 seconds. Plates were inverted over a beaker of Virkon sterilizing solution, dried by patting down on absorbent paper, washed three times with sterile Milli-Q grade and dried by patting down on absorbent paper.

After treatment and washing, 200  $\mu$ l of BHI followed by 80  $\mu$ l of sterile light mineral oil was added to each well. 10 Plates were incubated at 37°C in a microtitre plate reader (Dynex Technologies DIAS) and growth monitored at 630 nm every 15 minutes for 16 hours. The end-point was taken as the time taken to reach an  $A_{630}$  of 0.4. This absorbance approximated to the inflection point of the growth curve 15 for each bacterium, where growth of the culture is most rapid. The point of maximum growth rate was taken as it is the least sensitive to variations in the background absorbance and the most sharply resolved point on the time axis. The time to reach the optical density of 0.4 was 20 recorded. The longer the growth time, the more effective the treatment.

In a conventional toothpaste containing chalk as the abrasive cleaning agent, the following results were 25 obtained:

Time to reach the optical density (O.D.) of 0.4 (in hrs)	% by weight of Cu (as CuSO <sub>4</sub> )	% by weight of maltol
5.32	-	-
5.39	0.1	-
5.14	-	0.1
12.29	0.1	0.1
4.15	-	0.2
10.26	0.1	0.2

These results show, that the copper (II)-maltol complex (formed in situ as evidenced by the formation of a green 5 colour in the paste) has a significantly greater antibacterial effect than either CuSO<sub>4</sub> or maltol alone, as evidenced by the significantly longer periods to reach the O.D. of 0.4

10 Repeating these tests with a conventional toothpaste containing silica as the abrasive agent gave the following results:

Time to reach the (O.D.) of 0.4 (in hrs)	% by weight of Cu (as CuSO <sub>4</sub> )	% by weight of maltol
4.88	-	-
6.20	0.1	-
5.10	-	0.1
13.86	0.1	0.1
4.79	-	0.2
12.92	0.1	0.2

These results also clearly show the superiority of the copper (II)-maltol complex over coppersulphate as antibacterial agent.

- 5 Repeating these experiments in a model toothpaste solution gave the following results

Time to reach the optical density (O.D.) of 0.4 (in hrs)	% by weight of Cu (as CuSO <sub>4</sub> )	% by weight of maltol
4.34	-	-
6.49	0.1	-
4.38	-	0.1
9.39	0.1	0.1
4.69	-	0.2
9.57	0.1	0.2

- 10 For comparison, 0.25% of CuSO<sub>4</sub> and 0.25% hinokitiol produced a growth time to reach the O.D. of 0.4 of 7 hrs, 0.25% CuSO<sub>4</sub> alone 4.82 hrs, 0.25% hinokitiol alone 4.54 hrs.

- 15 Increasing the amounts of maltol, at a level of CuSO<sub>4</sub> of 0.1%, gave the following results in the above model toothpaste solution test

Time to (O.D.) of 0.4 (in hrs)	% by weight of maltol
4.03	--
9.66	0.1
9.72	0.2

12

9.38

0.5

8.55

1

In all the above tests, the copper(II) sulphate was its pentahydrate salt.

5 Similar results are obtained when using the zinc, iron and stannous complexes of maltol and ethylmaltol.

### Example 2

10 The following toothpastes were prepared:

PRODUCT _____ _____ _____ INGREDIENT	1. (PLACEBO)	2.	3.	4.
SORBITOL (70%)	45.00	45.00	45.00	45.00
SODIUM SACCHARIN	0.17	0.17	0.17	0.17
TITANIUM DIOXIDE	1.00	1.00	1.00	1.00
POLYETHYLENE GLYCOL 1500	5.00	5.00	5.00	5.00
THICKENING SILICA	8.00	8.00	8.00	8.00
ABRASIVE SILICA	10.00	10.00	10.00	10.00
CELLULOSE GUM	0.90	0.90	0.90	0.90
SODIUM LAURYL SULPHATE	1.50	1.50	1.50	1.50
FLAVOUR	1.00	1.00	1.00	1.00
COPPER SULPHATE PENTAHYDRATE	-	0.20	0.20	0.20
HINOKITIOL	-	-	0.20	-

ETHYLMALTOL	-	-	-	0.20
ETHANOL	-	-	-	1.0
WATER	TO 100%	TO 100%	TO 100%	TO 100%

5 The plaque inhibition (PGI) by these products was measured according to the plaque growth inhibition test method as described by Harrap in J. Clin. Periodontol (1) (1974) pp. 166-174, using single brushing and product 1 as placebo, and measuring the plaque at the beginning of the test and 10 after 18 hours. The PGI is expressed as a percentage according to the formula:


$$PGI(\%) = \left\{ 1 - \frac{PG_{18 \text{ hrs}(\text{test})} - PG_0 \text{ hrs}(\text{test})}{PG_{18 \text{ hrs}(\text{placebo})} - PG_0 \text{ hrs}(\text{placebo})} \right\} \times 100$$

Product	PGI(%)	Std. Error	p
2	15.16	11.43	n.s.
3	11.98	12.45	n.s.
4	26.31	10.686	0.026

20 These results show, that the copper(II) ethylmaltol complex has a significantly higher PGI than the placebo, whereas the PGI of copper alone or the copper-hinokitioi complex was not significantly different from the placebo.

# Claims

1. An oral care composition comprising a copper-, zinc, iron or stannous compound as antiplaque agent, characterised in that the compound is a complex of divalent copper, zinc, iron or tin, or trivalent iron, bonded to a biologically active ligand which is a cyclic  $\alpha$ -hydroxyketone of the following general formula:



in which X represents O or NR<sub>3</sub>, R<sub>1</sub> and R<sub>3</sub> represent H or a C<sub>1</sub>-C<sub>16</sub> branched or straight-chain alkylgroup, and R<sub>2</sub> represents H or a hydroxymethylgroup, the link between the carbon atoms in the ring structure at positions 2 and 3 being saturated or unsaturated.

2. An oral care composition according to claim 1, characterized in that the link is unsaturated.
3. A composition according to claim 1 or 2, characterized in that R<sub>1</sub> and R<sub>3</sub> represent H or a C<sub>1</sub>-C<sub>4</sub> branched or straight-chain alkyl group.



4. An oral care composition according to claims 1-3, characterised in that the complex is a divalent copper complex.
5. An oral care composition according to claims 1-4, characterised in that the cyclic  $\alpha$ -hydroxyketone is ethylmaltol.
6. The use of complexes of divalent copper, zinc, iron or tin, or trivalent iron, bonded to a cyclic  $\alpha$ -hydroxyketone according to the formula of claim 1, as an antimicrobial, antiplaque or anti-gingivitis agent in the manufacture of an oral care composition.

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/07380

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K7/16

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 1 507 846 A (THE PROCTER AND GAMBLE CO.) 19 April 1978 (1978-04-19) claim 1	1,4-6
A	US 5 037 634 A (WILLIAMS, D. R. ET AL.) 6 August 1991 (1991-08-06) column 06; claims 1,6-8	1,4
A	US 5 587 147 A (DOMKE, T. W. ET AL.) 24 December 1996 (1996-12-24) claims 1,5,6	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

**Special categories of cited documents:**

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

12 January 2000

Date of mailing of the international search report

21/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Beyss, E

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/07380

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 1507846	A	19-04-1978	AT 345988 B	10-10-1978
			AT 618875 A	15-02-1978
			AU 8342975 A	03-02-1977
			BE 832297 A	11-02-1976
			CA 1042806 A	21-11-1978
			DE 2534887 A	26-02-1976
			DK 357275 A	10-02-1976
			FR 2281107 A	05-03-1976
			IE 41307 B	05-12-1979
			JP 51041446 A	07-04-1976
			NL 7509469 A	11-02-1976
			SE 7508867 A	10-02-1976
			US 4051234 A	27-09-1977
US 5037634	A	06-08-1991	CA 2049085 A,C	17-02-1992
			EP 0471396 A	19-02-1992
			JP 1955589 C	28-07-1995
			JP 4279516 A	05-10-1992
			JP 6088896 B	09-11-1994
US 5587147	A	24-12-1996	CA 2152983 A	31-12-1995